These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 30506692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Loomba R, Jain A, Diehl AM, Guy CD, Portenier D, Sudan R, Singh S, Faulkner C, Richards L, Hester KD, Okada L, Li XJ, Mimms L, Abdelmalek MF.
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
    [Abstract] [Full Text] [Related]

  • 3. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ.
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [Abstract] [Full Text] [Related]

  • 4. Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease.
    Jahnel J, Zöhrer E, Alisi A, Ferrari F, Ceccarelli S, De Vito R, Scharnagl H, Stojakovic T, Fauler G, Trauner M, Nobili V.
    J Pediatr Gastroenterol Nutr; 2015 Jul; 61(1):85-90. PubMed ID: 25729888
    [Abstract] [Full Text] [Related]

  • 5. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, Fathi SA, Attia D, AbdAllah M.
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek M, Behling C, Richards L, Sirlin C, Loomba R.
    Hepatology; 2020 Mar; 71(3):849-860. PubMed ID: 31556124
    [Abstract] [Full Text] [Related]

  • 10. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
    Lubner MG, Graffy PM, Said A, Watson R, Zea R, Malecki KM, Pickhardt PJ.
    AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
    [Abstract] [Full Text] [Related]

  • 11. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Mandelia C, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N.
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
    [Abstract] [Full Text] [Related]

  • 12. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O, Colak Y, Senates E, Yilmaz Y, Ulasoglu C, Doganay L, Ozkanli S, Oltulu YM, Coskunpinar E, Tuncer I.
    World J Gastroenterol; 2015 Jul 14; 21(26):8096-102. PubMed ID: 26185381
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA.
    Eur J Radiol; 2018 Jan 14; 98():82-89. PubMed ID: 29279175
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
    Pacifico L, Bonci E, Marandola L, Romaggioli S, Bascetta S, Chiesa C.
    World J Gastroenterol; 2014 Dec 07; 20(45):17107-14. PubMed ID: 25493023
    [Abstract] [Full Text] [Related]

  • 19. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.
    Yilmaz Y, Eren F.
    Eur J Gastroenterol Hepatol; 2019 Jan 07; 31(1):43-46. PubMed ID: 30134384
    [Abstract] [Full Text] [Related]

  • 20. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.
    Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, Ikhwan MA, Bassirian S, Cepin S, Gonzalez MP, Mendler M, Kono Y, Vodkin I, Mekeel K, Haldorson J, Hemming A, Andrews B, Salotti J, Richards L, Brenner DA, Sirlin CB, Loomba R, Familial NAFLD Cirrhosis Research Consortium.
    J Clin Invest; 2017 Jun 30; 127(7):2697-2704. PubMed ID: 28628033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.